the effect of letrozole on endometrial thickness
Phase 3
Recruiting
- Conditions
- Female Infertility.Female infertility
- Registration Number
- IRCT20120104008611N14
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Women diagnosed with infertility
IVF candidate women
Exclusion Criteria
pregnancy
Presence of endometrial pathological lesions
The person's lack of consent to participate in the study
Intolerance of Letrozole in the patient
Presence of Letrozole contraindications in patients such as liver diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assess endometrial thickness. Timepoint: The second or third day of the menstrual cycle. Method of measurement: sonography.
- Secondary Outcome Measures
Name Time Method Biochemical pregnancy. Timepoint: Once, 14 days after fetus transfer. Method of measurement: Blood sampling.;Clinical pregnancy. Timepoint: Once, 6 to 8 weeks after embryo transfer. Method of measurement: Observation of pregnancy sac and heart rate on ultrasound.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms mediate letrozole's impact on endometrial thickness in IVF patients?
How does letrozole compare to estrogen-based therapies in improving endometrial receptivity for IVF?
Which biomarkers correlate with endometrial response to letrozole in phase III trials for infertility?
What adverse events are associated with letrozole use in endometrial preparation for IVF, and how are they managed?
Are there combination therapies involving letrozole and GnRH agonists that enhance endometrial growth in IVF candidates?